RxDoctor Payments Data

Joseph Angelo, MD

Internal Medicine · Bel Air, MDNPI 1740351147

Payments from drug & device makers

$8,737in general payments, 2019–2025

Across 465 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$836
  • AstraZeneca$694
  • Lilly USA, LLC$652
  • Boehringer Ingelheim$616
  • Pfizer$596
  • AbbVie$566
  • plus $5K from 52 others

What the payments were for

  • Food & beverage$8,55198%
  • Education$1862%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk36$836
AstraZeneca(2 entities)35$694
Lilly USA, LLC43$652
Boehringer Ingelheim24$616
Pfizer47$596
AbbVie(2 entities)40$566
GSK23$455
Esperion Therapeutics, Inc.30$421
Amgen(2 entities)18$410
Johnson & Johnson9$247
Novartis12$241
Amarin Pharma, Inc.12$218
Antares Pharma, Inc.10$171
Abbott10$170
Dexcom, Inc.7$160
Bayer7$153
Astellas Pharma US Inc4$128
Exact Sciences6$118
E.r. Squibb & Sons, L.L.C.7$112
Sumitomo Pharma America, Inc.5$111
Teleflex LLC1$111
Zyla Life Sciences, Inc.1$102
Idorsia Pharmaceuticals US Inc5$99
Sanofi-aventis U.S. LLC5$99
Takeda Pharmaceuticals U.S.A., Inc.4$84
Globus Medical3$81
Biohaven Pharmaceutical Holding Company Ltd.4$70
Xeris Pharmaceuticals, Inc.4$66
Almatica Pharma LLC3$64
Supernus Pharmaceuticals, Inc.4$63
Merck4$59
Corcept Therapeutics3$56
Sunovion Pharmaceuticals Inc.3$53
Phathom Pharmaceuticals, Inc.3$52
Grifols USA, LLC3$48
Inspire Medical Systems, Inc.2$47
Teva Pharmaceuticals USA, Inc.2$45
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$43
Circassia Inc.2$38
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$31
Kowa Pharmaceuticals America, Inc.2$30
Sanofi Pasteur Inc.1$28
Optinose US, Inc.1$27
Genentech USA, Inc.1$25
Lundbeck LLC1$25
Ultragenyx Pharmaceutical Inc.1$22
Jazz Pharmaceuticals Inc.1$21
Biohaven Pharmaceuticals, Inc.1$20
Avanir Pharmaceuticals, Inc.1$19
Halozyme Inc1$18
Aytu Biopharma, Inc.1$17
Kyowa Kirin, Inc.1$17
Eisai Inc.1$15
Assertio Therapeutics, Inc.1$15
Ironwood Pharmaceuticals, Inc1$15
Medtronic1$14
Acerus Pharmaceuticals Corporation1$13
Mylan Specialty L.p.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,737 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$190,564
Medicare patients
363
Services billed
2,821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide168$271,598
JardianceEmpagliflozin135$169,764
TrulicityDulaglutide89$158,517
FarxigaDapagliflozin Propanediol126$154,559
EliquisApixaban93$124,399
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$92,087
MounjaroTirzepatide62$79,232
NexletolBempedoic Acid57$54,480
Repatha SyringeEvolocumab31$42,262
BiktarvyBictegrav/Emtricit/Tenofov Ala11$41,802
XareltoRivaroxaban29$37,592
MyrbetriqMirabegron45$35,503
Nurtec OdtRimegepant Sulfate15$32,128
LinzessLinaclotide29$29,956
VascepaIcosapent Ethyl43$29,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$836$271,598168 claims
Lilly USA, LLCTrulicity, Mounjaro$652$237,749151 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$616$202,899167 claims
PfizerEliquis, Nurtec Odt$596$156,527108 claims
AstraZenecaFarxiga$694$154,559126 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$455$111,59398 claims
Esperion Therapeutics, Inc.Nexletol$421$54,48057 claims
Johnson & JohnsonXarelto$247$37,59229 claims
Astellas Pharma US IncMyrbetriq$128$35,50345 claims
AbbVieLinzess, Synthroid$566$34,70697 claims
Sumitomo Pharma America, Inc.Gemtesa$111$11,84016 claims
MerckJanuvia$59$6,99713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Bel Air

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →